Meta Biomed Co., Ltd. (KOSDAQ:059210)
South Korea · Delayed Price · Currency is KRW 3,530.00
-10.00 (-0.28%)
At close: Jun 10, 2026
Meta Biomed Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 99,671 | 102,951 | 94,036 | 83,101 | 68,942 | 58,780 |
Other Revenue | 0 | - | - | -0 | -0 | -0 |
| 99,671 | 102,951 | 94,036 | 83,101 | 68,942 | 58,780 | |
Revenue Growth (YoY) | 0.44% | 9.48% | 13.16% | 20.54% | 17.29% | 30.63% |
Cost of Revenue | 46,302 | 49,358 | 46,675 | 45,110 | 39,746 | 33,778 |
Gross Profit | 53,370 | 53,593 | 47,361 | 37,990 | 29,196 | 25,003 |
Selling, General & Admin | 26,472 | 26,272 | 23,143 | 21,651 | 18,682 | 15,455 |
Research & Development | 5,363 | 4,967 | 5,140 | 4,538 | 4,343 | 3,339 |
Operating Expenses | 32,938 | 32,399 | 30,139 | 27,388 | 23,831 | 19,741 |
Operating Income | 20,431 | 21,194 | 17,222 | 10,602 | 5,365 | 5,261 |
Interest Expense | -2,354 | -2,846 | -3,742 | -2,315 | -1,390 | -1,145 |
Interest & Investment Income | 1,067 | 1,123 | 635.32 | 375.03 | 206.78 | 29.82 |
Earnings From Equity Investments | 626.8 | 640.87 | - | - | - | 537.62 |
Currency Exchange Gain (Loss) | 1,105 | -427.77 | 3,453 | 232.84 | -523.93 | 1,509 |
Other Non Operating Income (Expenses) | -7,790 | -6,631 | 4,212 | -861.26 | -734.59 | 1,171 |
EBT Excluding Unusual Items | 13,087 | 13,053 | 21,781 | 8,034 | 2,923 | 7,364 |
Gain (Loss) on Sale of Investments | -1,015 | 300.42 | 1,530 | 773.17 | 426.74 | -39.83 |
Gain (Loss) on Sale of Assets | -2.78 | -52.74 | -13.88 | 12.62 | 47.62 | 801.18 |
Asset Writedown | -707.61 | -707.61 | - | -1,015 | -487.37 | -541.23 |
Pretax Income | 11,361 | 12,593 | 23,297 | 7,805 | 2,910 | 7,584 |
Income Tax Expense | 1,845 | 1,822 | 1,146 | -2,223 | 64.5 | -1,938 |
Earnings From Continuing Operations | 9,516 | 10,772 | 22,150 | 10,027 | 2,846 | 9,521 |
Earnings From Discontinued Operations | - | - | 174.43 | -211.99 | 754.18 | 140.51 |
Net Income to Company | 9,516 | 10,772 | 22,325 | 9,815 | 3,600 | 9,662 |
Minority Interest in Earnings | 265.01 | 216.8 | 77.62 | 265 | -972.22 | -140.45 |
Net Income | 9,781 | 10,988 | 22,402 | 10,080 | 2,628 | 9,522 |
Net Income to Common | 9,781 | 10,988 | 22,402 | 10,080 | 2,628 | 9,522 |
Net Income Growth | -56.37% | -50.95% | 122.24% | 283.61% | -72.40% | - |
Shares Outstanding (Basic) | 26 | 25 | 23 | 23 | 23 | 23 |
Shares Outstanding (Diluted) | 26 | 25 | 27 | 23 | 23 | 23 |
Shares Change (YoY) | -7.47% | -7.40% | 18.55% | -0.06% | -0.07% | -0.61% |
EPS (Basic) | 375.08 | 437.65 | 979.63 | 440.75 | 114.82 | 415.77 |
EPS (Diluted) | 375.08 | 437.65 | 655.73 | 440.75 | 114.82 | 415.77 |
EPS Growth | -42.14% | -33.26% | 48.78% | 283.85% | -72.38% | - |
Free Cash Flow | -1,405 | -471.17 | 11,719 | -1,271 | -6,236 | 9,069 |
Free Cash Flow Per Share | -53.86 | -18.77 | 432.22 | -55.59 | -272.48 | 396.00 |
Dividend Per Share | 105.000 | 105.000 | 30.000 | 20.000 | 20.000 | 20.000 |
Dividend Growth | 250.00% | 250.00% | 50.00% | - | - | 100.00% |
Gross Margin | 53.55% | 52.06% | 50.36% | 45.72% | 42.35% | 42.54% |
Operating Margin | 20.50% | 20.59% | 18.31% | 12.76% | 7.78% | 8.95% |
Profit Margin | 9.81% | 10.67% | 23.82% | 12.13% | 3.81% | 16.20% |
Free Cash Flow Margin | -1.41% | -0.46% | 12.46% | -1.53% | -9.04% | 15.43% |
EBITDA | 26,168 | 26,694 | 22,203 | 14,825 | 9,225 | 8,832 |
EBITDA Margin | 26.25% | 25.93% | 23.61% | 17.84% | 13.38% | 15.02% |
D&A For EBITDA | 5,737 | 5,499 | 4,981 | 4,223 | 3,860 | 3,571 |
EBIT | 20,431 | 21,194 | 17,222 | 10,602 | 5,365 | 5,261 |
EBIT Margin | 20.50% | 20.59% | 18.31% | 12.76% | 7.78% | 8.95% |
Effective Tax Rate | 16.24% | 14.47% | 4.92% | - | 2.22% | - |
Advertising Expenses | - | 387.86 | 298.35 | 151.08 | 230.86 | 245.85 |